Swisse and Biostime’s parent firm Health and Happiness Group (H&H Group) is adopting a ‘rotating CEO’ model after its most recent leader stepped down following a 2.5-month stint to pursue ‘other personal and professional interests’.
Demand for paediatric probiotics and nutritional supplements in mainland China declined in Q3, as parents were shopping less in pharmacies for immunity related products, according to Hong Kong-headquartered Health and Happiness Group (H&H Group).
The paediatric probiotics business has helped to offset a revenue slump in the infant formula business in China for Health and Happiness Group (H&H Group), while its adult nutrition portfolio surged by 55 per cent.
See the latest developments from health and nutrition brands across Asia-Pacific, including Youvit's plans in developing new product formats with investment from Unilever, the formulation of Biostime's China-approved infant formulas, and Turkish...
Biostime’s newly approved infant formulas in China are using osteopontin from bovine milk, also known as lactopontin (LPN), as one of the key ingredients, said parent firm Health and Happiness Group (H&H Group).
Human milk oligosaccharide (HMO) is one of the hottest and most commonly seen ingredients in Vietnam’s infant formula products these days, according to Vietnam homegrown firm Vinamilk and Hong Kong-headquarted Health & Happiness Group (H&H Group),...
Swisse’s double digital growth in mainland China and growing business in APAC have cushioned parent company Health and Happiness Group (H&H Group) from a challenging baby nutrition market.
Hong Kong-listed nutrition giant Health and Happiness (H&H) has reported mixed Q1 results, with strong year-on-year sales growth in infant milk formula failing to offset a decline in immunity-related products and probiotics.
Hong Kong-listed nutrition giant Health & Happiness has unveiled how it plans to expand its Swisse and Biostime brands globally, after unveiling full-year revenue growth of 2.5 per cent revenue growth.
Existing research on human milk oligosaccharides (HMOs) is only at the tip of the iceberg and there are vast opportunities for developing new pre/probiotics/synbiotics with HMOs, says an expert specialising in this field.
